# Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

> **NCT00570128** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 129 (actual)

## Conditions studied

- Down Syndrome

## Interventions

- **DRUG:** Donepezil HCl
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00570128
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11-16
- **Primary completion:** 2008-09-05
- **Final completion:** 2008-09-05
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2021-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00570128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00570128, "Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00570128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*